Demystifying Cannabis Shatter: A Deep Dive into Its Unique Qualities
In recent years, the world of cannabis concentrates has expanded rapidly, offering consumers a plethora of options to explore. One such concentrate that has
The Drug Enforcement Agency has been in conversation with the FDA on medical marijuana research and its status as a Schedule 1 drug.
A letter from the DEA dated April 4th (and released by the Huffington Post April 5th) addressed recent questions from several of the Democratic Senators cosponsoring The Compassionate Access, Research Expansion and Respect States (CARERS) Act, a proposition introduced in March of 2015 to shield from federal law those abiding by their state marijuana regulations, expand research, and make marijuana a Schedule II drug. While that bill is stuck in Senate limbo, the DEA may be looking to make that schedule change anyway.
The bombshell in the letter isn’t that the DEA is considering a recommendation on rescheduling marijuana (mainly because there is no indication what that recommendation will be) but that there are “hopes to release its determination in the first half of 2016.” In addition to marijuana, CBD is being evaluated for scheduling determination as an isolated drug.
A Schedule 1 Drug by definition has no medical benefit (as well as a “high potential for abuse”; therefore, changing its schedule has always depended on medical research. In addition to an inventory of the current marijuana available for federal research at the University of Mississippi, the letter discusses the potential to “increase the number of permits for the bulk manufacture of marijuana for research purposes,” in anticipation of the need for additional study and genetic variety in federal research.
It looks like the DEA is interested in expanding federal research beyond a single grow facility and 265 registered researchers. Looking at the breakdown of the marijuana available for research (the facility produces Placebo and Low, Medium, High and Very High THC varieties, each of which contain strains with very low to very high CBD content), it’s not hard to see that genetic variety is sorely needed in order to expand medical study to encompass each component of the endocannabinoid system.
The long-overdue removal of marijuana from Schedule 1 would signal the federal acknowledgement of marijuana as medicine and turn a major page in the story of medical cannabis. At NuVue Pharma, we’re watching to see if that day is coming in 2016.
In recent years, the world of cannabis concentrates has expanded rapidly, offering consumers a plethora of options to explore. One such concentrate that has
In the heart of the picturesque landscape of Gunnison, Colorado, a new beacon of cannabis culture has emerged. NuVue Pharma, the renowned cannabis dispensary chain,
As the cannabis industry continues to evolve, so do the ways we can access our favorite products. Online ordering for pickup has become a game-changer
In recent years, the conversation surrounding cannabis has shifted from taboo to a more open and accepting dialogue. One area gaining attention is
Cannabis cultivation has come a long way, and enthusiasts are often keen on preserving their harvest for extended periods. The key to maintaining the
It’s the company’s sixth location in Colorado. By Joseph Williams Journal staff writer for The Durango Herald Amid a statewide decline in cannabis sales, NuVue Pharma
Cannabis cultivation is an art, and every artist knows that the beauty of their masterpiece lies in the details. The flowering stage is one of
Rick Simpson Oil, named after its creator, Rick Simpson, is a highly concentrated cannabis extract known for its potential medicinal benefits. It’s made by extracting
Let’s dive into one of the most critical aspects of our beloved plant: amber trichomes! What are Amber Trichomes? Trichomes are those tiny, hair-like structures
Cannabis enthusiasts, rejoice! Cortez, Colorado is now home to an exciting addition to the NuVue Pharma dispensary chain that’s causing a buzz in the local